These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27886573)

  • 1. Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles.
    Read J; Ingram A; Al Saleh HA; Platko K; Gabriel K; Kapoor A; Pinthus J; Majeed F; Qureshi T; Al-Nedawi K
    Eur J Cancer; 2017 Jan; 70():62-74. PubMed ID: 27886573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in the expression of androgen receptor, wild type-epidermal growth factor receptor and a mutant epidermal growth factor receptor in human prostate cancer.
    Olapade-Olaopa EO; Moscatello DK; MacKay EH; Sandhu DP; Terry TR; Wong AJ; Habib FK
    Afr J Med Med Sci; 2004 Sep; 33(3):245-53. PubMed ID: 15819472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular Vesicles in the Adaptive Process of Prostate Cancer during Inhibition of Androgen Receptor Signaling by Enzalutamide.
    Soekmadji C; Rockstroh A; Ramm GA; Nelson CC; Russell PJ
    Proteomics; 2017 Dec; 17(23-24):. PubMed ID: 29105980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The androgen receptor and prostate cancer invasion.
    Bonaccorsi L; Muratori M; Marchiani S; Forti G; Baldi E
    Mol Cell Endocrinol; 2006 Feb; 246(1-2):157-62. PubMed ID: 16376012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines.
    Bonaccorsi L; Nosi D; Muratori M; Formigli L; Forti G; Baldi E
    J Mol Endocrinol; 2007 Feb; 38(1-2):51-66. PubMed ID: 17242169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells.
    Bonaccorsi L; Muratori M; Carloni V; Marchiani S; Formigli L; Forti G; Baldi E
    Steroids; 2004 Aug; 69(8-9):549-52. PubMed ID: 15288768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
    Mulholland DJ; Read JT; Rennie PS; Cox ME; Nelson CC
    Oncogene; 2003 Aug; 22(36):5602-13. PubMed ID: 12944908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer.
    Zhu C; Zhu Q; Wu Z; Yin Y; Kang D; Lu S; Liu P
    J Cell Physiol; 2018 Feb; 233(2):1104-1119. PubMed ID: 28422286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli.
    Mulholland DJ; Cheng H; Reid K; Rennie PS; Nelson CC
    J Biol Chem; 2002 May; 277(20):17933-43. PubMed ID: 11856748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
    Liu Y; Majumder S; McCall W; Sartor CI; Mohler JL; Gregory CW; Earp HS; Whang YE
    Cancer Res; 2005 Apr; 65(8):3404-9. PubMed ID: 15833875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor-beta1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells.
    Gerdes MJ; Dang TD; Larsen M; Rowley DR
    Endocrinology; 1998 Aug; 139(8):3569-77. PubMed ID: 9681509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine-based liquid biopsy: non-invasive and sensitive AR-V7 detection in urinary EVs from patients with prostate cancer.
    Woo HK; Park J; Ku JY; Lee CH; Sunkara V; Ha HK; Cho YK
    Lab Chip; 2018 Dec; 19(1):87-97. PubMed ID: 30500003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
    Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
    Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer.
    Narayanan R; Yepuru M; Szafran AT; Szwarc M; Bohl CE; Young NL; Miller DD; Mancini MA; Dalton JT
    Cancer Res; 2010 Jan; 70(2):842-51. PubMed ID: 20068182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
    Mukherjee B; Mayer D
    Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms.
    Periyasamy S; Warrier M; Tillekeratne MP; Shou W; Sanchez ER
    Endocrinology; 2007 Oct; 148(10):4716-26. PubMed ID: 17615153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines.
    Nakauchi H; Matsuda K; Ochiai I; Kawauchi A; Mizutani Y; Miki T; Kawata M
    J Histochem Cytochem; 2007 Jun; 55(6):535-44. PubMed ID: 17312014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer: a model of integration of genomic and non-genomic effects of the androgen receptor in cell lines model.
    Bonaccorsi L; Nosi D; Quercioli F; Formigli L; Zecchi S; Maggi M; Forti G; Baldi E
    Steroids; 2008 Oct; 73(9-10):1030-7. PubMed ID: 18358509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
    Migliaccio A; Di Domenico M; Castoria G; Nanayakkara M; Lombardi M; de Falco A; Bilancio A; Varricchio L; Ciociola A; Auricchio F
    Cancer Res; 2005 Nov; 65(22):10585-93. PubMed ID: 16288052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.